Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Adam Maeder
Period: Reporting periods mapped to calendar 2025 Q1 – 2025 Q3 (3 quarters).
- Questions
- 4on tracked calls
- Challenge rate
- 0%none of 4 questionsLimited sample
- Companies
- 2questioned at least once
- Reporting periods
- 3with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 4 of 4 questions from 2 companies
ISRGIntuitive Surgical3 questions · 3 reporting periods · 0 of 3 challenging
Calendar 2025 Q3
I was wondering if you could share just a little bit more kind of early feedback that you've gathered to date
Show response
Jamie noted healthy pipelines in both markets but some incremental cost sensitivity to DV5 pricing relative to US, with early adopter institutions most interested.
Calendar 2025 Q2
I did want to ask about the curve vessel sealer, which recently got FDA approval have been seeing some buzz on LinkedIn
Show response
Jamie described the curved vessel sealer as enabling deeper penetration in thoracic, colorectal, and hiatal hernia procedures with minor positive I&A per procedure impact.
Calendar 2025 Q1
can you just maybe give us a little bit more color around the percentage of DV5 cases that are using force sensing instruments today?
Show response
Jamie noted six instruments currently enabled for force feedback with many thousands of cases performed. Gary clarified that usage is artificially limited by manufacturing supply constraints, not demand.
ABTAbbott Laboratories1 question · 1 reporting period · 0 of 1 challenging
Calendar 2025 Q2
first I was hoping for an update on [ in formula ] litigation and the MDL process
Show response
Ford declined to comment on specific NEC cases, stood behind product safety. On dual analyte sensor, declined to share timing, pricing, or submission details but confirmed ~5 clinical trials completed.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| ISRG Intuitive Surgical | 3 | 0%none of 3 questions |
| ABT Abbott Laboratories | 1 | —Rate withheld: fewer than 3 questions |
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2025 Q1 | 1 | 0%none of 1 question | 1 |
| 2025 Q2 | 2 | 0%none of 2 questions | 2 |
| 2025 Q3 | 1 | 0%none of 1 question | 1 |
- 2025 Q11 question · challenge rate 0% (none of 1 question) · 1 company
- 2025 Q22 questions · challenge rate 0% (none of 2 questions) · 2 companies
- 2025 Q31 question · challenge rate 0% (none of 1 question) · 1 company
Topics
Topics tagged on this analyst’s questions.
- Product Launch4
- Innovation & R&D2
- Geographic Expansion1
- Regulation Policy1